Kathy McGee - Avita Therapeutics Chief Officer
| AVH Stock | 3.90 0.04 1.02% |
Executive
Kathy McGee is Chief Officer of Avita Therapeutics
| Age | 58 |
| Address | 28159 Avenue Stanford, Valencia, CA, United States, 91355 |
| Phone | 661 367 9170 |
| Web | https://www.avitamedical.com |
Avita Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4537) % which means that it has lost $0.4537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5244) %, meaning that it generated substantial loss on money invested by shareholders. Avita Therapeutics' management efficiency ratios could be used to measure how well Avita Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Avita Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 51.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 880 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Vincent Chin | Clime Investment Management | N/A | |
| Larina Tcherkezian | BKI Investment | N/A | |
| BCom BE | REGAL ASIAN INVESTMENTS | N/A | |
| James Trude | Clime Investment Management | N/A | |
| Steven Bennett | Charter Hall Retail | N/A | |
| LLB BA | National Storage REIT | N/A | |
| Kerry Thomas | Clime Investment Management | N/A | |
| Jaime Johns | Clime Investment Management | N/A | |
| Matt Rencken | Clime Investment Management | N/A | |
| Kara Boden | Clime Investment Management | N/A | |
| Mark Bryant | Charter Hall Retail | N/A | |
| Annick Donat | Clime Investment Management | N/A | |
| AAPI DipVal | Charter Hall Retail | N/A | |
| Claire LLB | National Storage REIT | N/A | |
| Andrew CPA | Clime Investment Management | N/A | |
| Joanne Donovan | Charter Hall Retail | N/A | |
| AAPI LLB | Charter Hall Retail | N/A | |
| Richard Stacker | Charter Hall Retail | N/A | |
| David Harrison | Charter Hall Retail | 58 | |
| Rob Horne | BKI Investment | N/A | |
| Gareth Abernethy | Clime Investment Management | N/A | |
Management Performance
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.45 |
Avita Therapeutics Leadership Team
Elected by the shareholders, the Avita Therapeutics' board of directors comprises two types of representatives: Avita Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avita. The board's role is to monitor Avita Therapeutics' management team and ensure that shareholders' interests are well served. Avita Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avita Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rob Hall, Senior Resources | ||
| James Corbett, President CEO | ||
| Michael MBA, Chief Officer | ||
| Jessica Ekeberg, Investor Executive | ||
| David OToole, Chief Officer | ||
| Kathy McGee, Chief Officer | ||
| Terry Bromley, Senior Sales | ||
| Katie Bush, Senior Affairs | ||
| Donna Shiroma, General Secretary | ||
| Ron Lagerquist, Senior Affairs | ||
| David Fencil, Senior Operations | ||
| Andrew Quick, Chief Officer | ||
| Debbie Garner, Senior Strategy | ||
| JD PMP, Senior Management | ||
| Nicole Kelsey, Chief Secretary | ||
| Erin Liberto, Chief Officer |
Avita Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avita Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.45 | ||||
| Profit Margin | (0.95) % | ||||
| Operating Margin | (0.71) % | ||||
| Current Valuation | 520.39 M | ||||
| Shares Outstanding | 129.95 M | ||||
| Shares Owned By Insiders | 0.17 % | ||||
| Price To Book | 27.45 X | ||||
| Price To Sales | 8.64 X | ||||
| Revenue | 50.14 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Avita Stock Analysis
When running Avita Therapeutics' price analysis, check to measure Avita Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avita Therapeutics is operating at the current time. Most of Avita Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avita Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avita Therapeutics' price. Additionally, you may evaluate how the addition of Avita Therapeutics to your portfolios can decrease your overall portfolio volatility.